Top

American Journal of Cardiovascular Drugs

Published in:

01-02-2012 | Current Opinion

Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes

Are We There Yet?

Authors: Angelo L. Gaffo, Dr Kenneth G. Saag

Published in: American Journal of Cardiovascular Drugs | Issue 1/2012

Abstract

Data supporting an association between high levels of serum urate and cardiovascular disease have continued to emerge. Basic science data, small clinical trials, and epidemiologic studies have provided support for the idea of a true causal effect. In this paper, we present evidence about the association between hyperuricemia and selected cardiovascular diseases. Although data generated so far compellingly support pharmacologic urate-lowering therapy in selected cases with high cardiovascular risk, further evidence is necessary before widely advocating this approach to prevent cardiovascular outcomes putatively associated with hyperuricemia.

Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15 (2): 189–92.PubMedCrossRef

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82 (3): 421–6.PubMedCrossRef

Puig JG, de Miguel E, Castillo MC, et al. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008; 27 (6): 592–5.PubMedCrossRef

Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther 2009; 11(4): 240. Epub 2009 Aug 19.PubMedCrossRef

Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2007; 58 (1): 26–35.CrossRef

Klemp P, Stansfield SA, Castle B, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56 (1): 22–6.PubMedCrossRef

Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283(5): F1 105–10.

Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67 (1): 237–47.PubMedCrossRef

Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008; 23 (4): 1179–85.PubMedCrossRef

10.

Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008; 108 (4): 69–78.CrossRef

11.

Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular reninangiotensin system. J Hypertens 2008; 26 (2): 269–75.PubMedCrossRef

12.

Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295(4): F1134–41.PubMedCrossRef

13.

Yu MA, Sanchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28 (6): 1234–42.PubMed

14.

Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417 (6887): 447–52.PubMed

15.

Hunt SC, Stephenson SH, Hopkins PN, et al. Predictors of an increased risk of future hypertension in Utah: a screening analysis. Hypertension 1991; 17 (6 Pt 2): 969–76.PubMedCrossRef

16.

Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24 (5): 531–6.PubMedCrossRef

17.

Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49 (2): 298–303.PubMedCrossRef

18.

Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42 (4): 474–80.PubMedCrossRef

19.

Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48 (6): 1037–42.PubMedCrossRef

20.

Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27 (11): 835–41.PubMedCrossRef

21.

Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18 (6): 523–30.PubMedCrossRef

22.

Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48 (6): 1031–6.PubMedCrossRef

23.

Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131 (6): 1017–27.PubMed

24.

Shankar A, Klein R, Klein BE, et al. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 2006; 20 (12): 937–45.PubMedCrossRef

25.

Sundstrom J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45 (1): 28–33.PubMed

26.

Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19 (7): 1209–15.PubMedCrossRef

27.

Gaffo AL, Jacobs Jr DR, Sijtsma F, et al. Serum urate levels in young adults are associated with the risk of incident hypertension: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. In: Meeting of the American College of Rheumatology. Atlanta (GA): 2010.

28.

Grayson PC, Kim SY, Lavalley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63 (1): 102–10.CrossRef

29.

Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009; 55 (11): 2026–34.PubMedCrossRef

30.

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300 (8): 924–32.PubMedCrossRef

31.

Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39 (4): 1227–33.PubMedCrossRef

32.

US National Institute of Health [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00241839?term=allopurinol+AND+hypertension&rank=3 [Accessed 2011 Jul 11].

33.

Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62(2): 170–80.

34.

Chen JH, Chuang SY, Chen HJ, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61 (2): 225–32.PubMedCrossRef

35.

Tatli E, Aktoz M, Buyuklu M, et al. The relationship between coronary artery disease and uric acid levels in young patients with acute myocardial infarction. Cardiol J 2008; 15 (1): 21–5.PubMed

36.

Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61 (7): 885–92.PubMedCrossRef

37.

Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69 (14): 1418–23.PubMedCrossRef

38.

Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556–62.PubMedCrossRef

39.

Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54 (2): 273–84.PubMedCrossRef

40.

Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125 (2): 232–9.PubMedCrossRef

41.

Wu AH, Ghali JK, Neuberg GW, et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010; 160 (5): 928–33.PubMedCrossRef

42.

Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006; 12 (7): 491–8.PubMedCrossRef

43.

Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol 2008; 51 (24): 2301–9.PubMedCrossRef

44.

Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131 (1): 7–13.PubMed

45.

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283 (18): 2404–10.PubMedCrossRef

46.

Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266 (21): 3008–11.PubMedCrossRef

47.

Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998 Aug. 47 (8): 929–33.PubMedCrossRef

48.

Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructoseinduced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290(3): F625–31.PubMedCrossRef

49.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321–33.PubMedCrossRef

50.

Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76 (1): 47–56.PubMedCrossRef

51.

Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65 (10): 1312–24.PubMedCrossRef

52.

Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8): 741–52.PubMedCrossRef

53.

Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004; 51 (6): 1023–9.PubMedCrossRef

54.

Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52 (1): 283–9.PubMedCrossRef

55.

Gaffo AL, Roseman JM, Jacobs Jr DR, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the coronary artery risk development in young adults (CARDIA) cohort. Ann Rheum Dis 2010; 69(11): 1965–70.PubMedCrossRef

56.

Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375 (9732): 2161–7.PubMedCrossRef

57.

Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2010; 377 (9760): 165–77.PubMedCrossRef

58.

European Medicines Agency [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/adenuric/adenuric.htm. [Accessed 2011 July 11].

59.

Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59 (11): 1580–8.PubMedCrossRef

60.

Kim SY, Martin N, Hsia EC, et al. Management of aortic disease in Marfan Syndrome: a decision analysis. Arch Intern Med 2005; 165 (7): 749–55.PubMedCrossRef

Title: Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes
Are We There Yet?
Authors: Angelo L. Gaffo
Dr Kenneth G. Saag
Publication date: 01-02-2012
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 1/2012
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.2165/11594580-000000000-00000

2024 ASCO Annual Meeting

Springer Medicine

Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes

Are We There Yet?

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia

Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus

Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension

Managing Arrhythmias before and after Aortic Valve Surgery in Children

Rivaroxaban